Readout Newsletter: Eli Lilly’s ‘triple-G’ drug delivers striking results
Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company is…
SuppCo launches certification to verify actives in dietary supplements
The new program complements SuppCo’s TrustScore supplement quality rating system and builds on earlier testing initiatives, which revealed…
Ocular Therapeutix wet AMD drug Axpaxli tops Eylea in study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Prasad overruled FDA staff to reject Moderna flu vaccine application
WASHINGTON — Top Food and Drug Administration official Vinay Prasad overruled the agency’s reviewers when he refused to accept…
Ivermectin for cancer? National Cancer Institute is ‘taking it seriously’
The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer,…
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
By Kamal Choudhury Feb 9 (Reuters) – Privately held Iambic said on Monday it has entered a multi-year…
Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
UnitedHealth shrinks, Medicare Advantage crackdown: Health Care Inc.
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Novo Nordisk, PBM reform, Grail: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
The new medicines and medical advances that defined 2025
It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series…
Pfizer, FDA, BioMarin, worst CEO of 2025: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…